EN DE
STOCK COMPARISON

Chongqing Lummy Pharmaceutical vs Eli Lilly and: Fair Value & Quality

Both stocks run through our valuation models. Here is how Chongqing Lummy Pharmaceutical (300006) and Eli Lilly and (LLY) compare, as of Sep 24, 2026.

As of Sep 24, 2026, Fair Value Calculator sees Eli Lilly and as the less overvalued of the two: Chongqing Lummy Pharmaceutical trades at ¥5.56 versus a fair value of ¥1.10 (-80%), while Eli Lilly and trades at $1,151 versus $791 (-31%).
Chongqing Lummy Pharmaceutical
300006.SHE · CNY · Health Care
-80%
upside to fair value
overvalued
Price¥5.56
Fair Value¥1.10
Quality50/100
Eli Lilly and
LLY · USD · Health Care
-31%
upside to fair value
overvalued
Price$1,151
Fair Value$791
Quality69/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

Chongqing Lummy PharmaceuticalEli Lilly and
Valuation
n/aP/E (TTM)40.9×
1.15×P/S (TTM)14.31×
0.50×P/B38.95×
n/aEV/EBITDA29.5×
n/aPEG1.54×
−80.2%Fair value upside−31.2%
0.2%Dividend yield0.5%
n/aDividend per share$6.23
Profitability
-3%Operating margin49%
n/aEBIT margin trend (5Y)1.42×
-7%Return on equity107%
-2%Return on assets21%
Growth
-8%Revenue growth (YoY)56%
-4.6%Avg. growth/yr (3Y)31.7%
-13.5%Avg. growth/yr (5Y)21.6%
n/aValue creation/yr+26.5%
Balance & size
n/aInterest coverage (EBIT/interest)37.3×
0.03×Debt / equity1.54×
$877MMarket cap$1.0T
weakGrowth qualitymixed

Eli Lilly and leads: 3 to 7 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Chongqing Lummy Pharmaceuticalof which business quality 51 · market factors 52 Eli Lilly andof which business quality 65 · market factors 78
ProfitabilityMargins and returns on capital today
8
85
Quality GrowthAre margins and returns improving?
20
86
CashflowEarnings quality: real cash, not paper profit
23
51
Fin. StrengthBalance sheet, leverage, solvency risk
98
53
InvestmentDisciplined investing over empire-building
95
15
Low VolatilityCalm price path (market factor)
53
77
MomentumPrice trend over the last 3–12 months (market factor)
50
75
52W MomentumDistance to the 52-week high (market factor)
53
85
Net IssuanceShare count: buybacks or dilution?
81
93

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyChongqing Lummy PharmaceuticalPrice ¥5.56Eli Lilly andPrice $1,151
DCF Models-80%below the price¥1.09-70%below the price$345
Earnings-Basedn/a-79%below the price$239
Dividend Discount-98%below the price¥0.12-90%below the price$115
Multiples-81%below the price¥1.07-69%below the price$358
Asset-Based-80%below the price¥1.11-98%below the price$19.94
Growth DCF-80%below the price¥1.11-83%below the price$197
Economic Profitn/a-70%below the price$347
Growth Earningsn/a-67%below the price$375
Minimum-98%below the price¥0.12-98%below the price$19.94
Maximum-80%below the price¥1.11-67%below the price$375
Median-80%below the price¥1.09-75%below the price$292
Geometric mean-87%below the price¥0.70-83%below the price$190

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Chongqing Lummy Pharmaceutical: 9 of 9 models see the stock below the current price.

Eli Lilly and: 26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Chongqing Lummy Pharmaceutical
Price ¥5.56
Fair Value ¥1.10
Bear ¥1.03Bull ¥1.21
Eli Lilly and
Price $1,151
Fair Value $791
Bear $401Bull $1,165

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Chongqing Lummy Pharmaceutical · Health Care

Quality score50 · below median
Fair value upside-80% · bottom 25%

Eli Lilly and · Health Care

Quality score69 · Top 25%
Fair value upside-31% · below median

Bottom line

As of Sep 24, 2026, Fair Value Calculator sees Eli Lilly and as the less overvalued of the two: Chongqing Lummy Pharmaceutical trades at ¥5.56 versus a fair value of ¥1.10 (-80%), while Eli Lilly and trades at $1,151 versus $791 (-31%).

Eli Lilly and has the higher quality score (69/100).

Open Eli Lilly and live analysis →
Chongqing Lummy Pharmaceutical · Eli Lilly and

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Chongqing Lummy Pharmaceutical

Microsoft vs NvidiaApple vs MicrosoftNvidia vs Taiwan Semiconductor ManufacturingApple vs Taiwan Semiconductor Manufacturing

Related to Eli Lilly and

Alphabet Inc Class C vs Meta PlatformsCisco Systems vs NvidiaMicrosoft vs Taiwan Semiconductor ManufacturingApple vs Cisco Systems
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.